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Introduction: Diffuse axonal injury is an extremely common type of traumatic brain injury encountered in motor
vehicle crashes, sports injuries, and in combat. Although many cases of diffuse axonal injury result in chronic
disability, there are no current treatments for this condition. Its basic lesion, traumatic axonal injury, has been
aggressively modeled in primate and rodent animal models. The inexorable axonal and perikaryal degeneration and
dysmyelination often encountered in traumatic axonal injury calls for regenerative therapies, including therapies
based on stem cells and precursors. Here we explore the proof of concept that treatments based on transplants of
human oligodendrocyte progenitor cells can replace or remodel myelin and, eventually, contribute to axonal
regeneration in traumatic axonal injury.
Methods: We derived human oligodendrocyte progenitor cells from the human embryonic stem cell line H9,
purified and characterized them. We then transplanted these human oligodendrocyte progenitor cells into the
deep sensorimotor cortex next to the corpus callosum of nude rats subjected to traumatic axonal injury based on
the impact acceleration model of Marmarou. We explored the time course and spatial distribution of differentiation
and structural integration of these cells in rat forebrain.
Results: At the time of transplantation, over 90 % of human oligodendrocyte progenitor cells expressed A2B5,
PDGFR, NG2, O4, Olig2 and Sox10, a profile consistent with their progenitor or early oligodendrocyte status. After
transplantation, these cells survived well and migrated massively via the corpus callosum in both injured and
uninjured brains. Human oligodendrocyte progenitor cells displayed a striking preference for white matter tracts
and were contained almost exclusively in the corpus callosum and external capsule, the striatopallidal striae, and
cortical layer 6. Over 3 months, human oligodendrocyte progenitor cells progressively matured into myelin basic
protein(+) and adenomatous polyposis coli protein(+) oligodendrocytes. The injured environment in the corpus
callosum of impact acceleration subjects tended to favor maturation of human oligodendrocyte progenitor cells.
Electron microscopy revealed that mature transplant-derived oligodendrocytes ensheathed host axons with spiral
wraps intimately associated with myelin sheaths.
Conclusions: Our findings suggest that, instead of differentiating locally, human oligodendrocyte progenitor cells
migrate massively along white matter tracts and differentiate extensively into ensheathing oligodendrocytes. These
features make them appealing candidates for cellular therapies of diffuse axonal injury aiming at myelin remodeling
and axonal protection or regeneration.* Correspondence: lxu9@jhmi.edu
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Axonal injury is the defining feature of diffuse axonal in-
jury (DAI), but is also present in blast injuries [1],
chronic traumatic encephalopathy [2], and even mild
head injuries [3]. Axonal damage in models of DAI is re-
ferred to as traumatic axonal injury (TAI), a term often
used interchangeably with DAI [4, 5]. In the case of
DAI, axonal injury causes disconnection of neural circuits
at multiple central nervous system (CNS) sites [6–8] and
can lead to a number of neurological impairments, includ-
ing long-term memory problems, emotional disturbances,
unconsciousness, and/or a persistent vegetative state.
These neurological impairments have no satisfactory treat-
ment besides symptomatic alleviation of various subsyn-
dromes with physical, occupational, speech and language
therapy and various categories of CNS-acting drugs in-
cluding antispasmodics, antidepressants, and mood stabi-
lizers. Although some retraining of circuits is anticipated
over time and syndromic pharmacotherapies have some
effectiveness, most patients with DAI still remain severely
symptomatic years and decades later.
Stem cell therapy presents a promising treatment ap-
proach for traumatic brain injury (TBI). Some early suc-
cess in models of ischemic brain injury [9] has
encouraged the use of stem cell or neural precursor
(NP) transplantation, primarily in models of focal TBI
[10]. Much less is known about the role of stem cell
therapies in DAI/TAI. Axonal repair as a target of treat-
ment separate from nerve cell regeneration is not as well
established in TBI as in spinal cord injury, and this is espe-
cially true with the problem of myelin repair/remyelination
[11]. However, demyelination appears to contribute to de-
generation of axons in TAI [12, 13] and TAI is associated
with active and ongoing attempts at axonal repair [14].
Therefore, adding exogenous oligodendrocyte progenitor
cells (OPCs) may furnish competent oligodendrocytes that
can assist in remyelination/myelin remodeling and prevent
axonal degeneration or help myelinate regenerating axons
in TAI.
Animal models are invaluable tools in establishing
proof of concept that remyelination by exogenously pro-
vided oligodendrocytes is possible in TAI settings.
Models of inertial acceleration and impact acceleration
(IA) are frequently used for experimental studies of
DAI/TAI [5, 15]. In the present study we use the IA
model of DAI/TAI [16] and transplant human embry-
onic stem cell (ESC)-derived OPCs (hOPCs) into the
deep sensorimotor cortex next to the corpus callosum.
Our findings indicate that exogenous hOPCs differenti-
ate into mature oligodendrocytes, migrate extensively
along white matter tracts, and begin to myelinate host
axons. Our data are consistent with the view that stem
cell grafts may serve as effective myelin remodeling tools
in TBI scenarios featured by DAI/TAI.Materials and methods
Human embryonic stem cell culture and differentiation to
human oligodendrocyte progenitor cells
The human ESC line H9 from WiCell (Madison, WI,
USA) was maintained according to standard stem cell
culture protocols. H9 cells (WA-09; passages 30 to 41)
were grown on mitotically inactivated mouse embryonic
fibroblasts essentially as described in [17]. hOPCs were
generated through extensive passaging as neurospheres
based on the method of Hu and colleagues [18, 19] with
minor modifications (Additional file 1: Fig. S1). The ven-
tralizing factor sonic hedgehog (SHH; 100 ng/mL) along
with the caudalizing factor retinoic acid (0.1 μM) were
used to initially pattern neuroepithelial cells; glial differ-
entiation medium (GDM; Dulbecco's modified Eagle's
medium (DMEM)/F12, B27 without vitamin A, N1,
MEM-NEAA, cAMP, biotin, 60 ng/mL triiodothyronine,
10 ng/mL platelet-derived growth factor (PDGF)-AA,
insulin-like growth factor (IGF)1 and neurotrophin
(NT)3) was used for further differentiation. Cells were
trypsinized with TrypLE (Life Technologies, Grand Island,
NY, USA) at day 84 after induction of differentiation,
counted, and plated on p-L-ornithine- and laminin-coated
plates. Cells were grown in GDM supplemented with
PDGF-AA, IGF1 and NT3 for 12 days, then trypsinized,
counted, and resuspended at high concentration (2.0 ×
108 per mL), and finally transplanted on day 98 after in-
duction of differentiation.
Characterization of human oligodendrocyte progenitor
cells used for transplantation with immunocytochemistry
Two weeks before transplantation (on day 84, a time point
chosen to correspond to the remaining time in differenti-
ation of hOPCs destined for transplantation), hOPC neu-
rospheres were trypsinized with TrypLE and counted.
Twenty thousand cells were plated on polyornithine- and
laminin-coated coverslips or Matrigel-coated four-well
slide chambers and cultured in GDM supplemented with
PDGF, IGF and NT3 for 2 weeks. Cultures were then fixed
with 4 % paraformaldehyde in phosphate-buffered saline
for 20 minutes and then subjected to immunocytochem-
istry with the oligodendrocytic markers A2B5, platelet-
derived growth factor receptor (PDGFR)α, NG2, Sox10,
and O4; the neuronal marker type III-tubulin epitope J1
(TUJ1); astrocyte marker glial fibrillary acidic protein
(GFAP); and the mesodermal marker bone morphogenetic
protein 4 (Table 1).
Animals and surgical procedures
Ten-week old male nude rats (Crl:NIH-Foxn1rnu;
Charles River, Wilmington, MA, USA) were used for
hOPC transplantation. Nude rats were chosen because
immunodeficient animals yield greater engraftment and
survival of human cells than immunocompetent animals
Table 1 Primary antibodies used for immunocytochemistry, immunohistochemistry and ultrastructural immunohistochemistry
Target phenotypes Target proteins/epitopes Host Dilution Vendor
Human cell markers Human Nuclei Protein antibody (HNu) Mouse 1:1,000 Millipore, Billerica, MA, USA
Human cytoplasm-specific antibody (SC121) Mouse 1:3,000 StemCells, Inc., CA, USA
Neuron (in vivo) Type III-tubulin epitope J1 (TUJ1) Rabbit 1:400 Covance, Berkeley, CA, USA
Neuron (in vitro) Type III-tubulin epitope J1 (TUJ1) Mouse 1:100 Sigma, Saint Louis, MO, USA
Mitotic marker Ki67 antigen (NCL-Ki67p) Rabbit 1:400 Novocastra Labs, Newcastle, UK
Axon Neurofilament heavy chain Rabbit 1:200 Sigma, Saint Louis, MO, USA
Progenitor/early oligodendrocyte Olig2 Goat 1:50 Santa Cruz, Santa Cruz, CA, USA
Platelet-derived growth factor receptor α (PDGFRα) Rabbit 1:100 Santa Cruz, Santa Cruz, CA, USA
A2B5 Mouse 1:200 Millipore, Billerica, MA, USA
NG2 Rabbit 1:100 Millipore, Billerica, MA, USA
O4 Mouse 1:100 Millipore, Billerica, MA, USA
Late oligodendrocyte Myelin basic protein (MBP) Rabbit 1:200 Abcam, Cambridge, MA, USA
Adenomatous polyposis coli protein (APC) Rabbit 1:200 Novus Biologicals, Littleton, CO, USA
Astrocyte (in vivo) Glial fibrillary acidic protein (GFAP) Rabbit 1:400 Dako, Carpinteria, CA, USA
Astrocyte (in vitro) Glial fibrillary acidic protein (GFAP) Rabbit 1:100 Millipore, Billerica, MA, USA
Mesodermal marker Bone morphogenetic protein-4 (BMP4) Mouse 1:300 Millipore, Billerica, MA, USA
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cedures were carried out according to protocols ap-
proved by the Animal Care and Use Committee of the
Johns Hopkins Medical Institutions using gas anesthesia
(isoflurane:oxygen:nitrous oxide = 1:33:66) and aseptic
methods. In order to explore the fate of transplanted
hOPCs and compare differentiation between injured and
uninjured scenarios, animals were separated into IA and
sham groups. In the IA group, animals were subjected to
injury with full artificial ventilation as described by
Marmarou and colleagues [16]. In the present experi-
ments, we employed a severe TBI regimen using a 450 g
weight that was freely dropped onto the steel disc
through a Plexiglass tube from a height of 2 meters. In
the sham group, animals received all aspects of the regi-
men except the injury itself (weight on the steel disc).
One week after injury, a time point that appears to optimize
survival and differentiation [21, 22], 200,000 live hOPCs
were transplanted into two sites 1 mm apart in the right
deep motor cortex next to the corpus callosum (1 mm and
0 mm anterior to bregma, 2 mm lateral to midline and
3 mm ventral to pia) of either injured (n = 10) or sham
(n = 5) animals using procedures that have been de-
tailed in our published work [21, 23, 24]. To explore
the progress of differentiation of transplanted hOPCs in the
TAI environment, animals in the TAI group were allowed
to survive for 6 weeks and 3 months. Sham animals with
transplanted hOPCs were euthanized at 3 months.
Histology, immunohistochemistry and microscopy
Brain tissues were prepared from animals perfused trans-
cardially with 4 % phosphate-buffered paraformaldehyde.The axonal injury, survival, location and phenotypic fate
of hOPC grafts were assessed with ABC peroxidase im-
munohistochemistry (IHC) and dual-label fluorescent
IHC in serial coronal or sagittal sections (40 μm) through
the brain as described previously [22, 24, 25]. Axonal
injury was studied with well-established TAI markers,
including an antibody against the amyloid precursor
protein (APP), the monoclonal antibody RMO14 bind-
ing to the rod domain of neurofilaments H and M, and
a monoclonal antibody against the 68-kDa light chain
neurofilament protein. hOPC survival was studied with
human-specific nuclei (HNu) or human-specific cyto-
plasm (SC121) antibody using immunoperoxidase or
immunofluorescence labeling. Differentiation was stud-
ied with dual-label immunofluorescence combining
HNu or SC121 with other oligodendrocyte markers -
that is, the progenitor and early marker PDGFRα, the
early markers O4 and GalC and late markers myelin
basic protein (MBP) and adenomatous polyposis coli pro-
tein (APC). Appositions between axons and transplant-
derived oligodendrocytes were visualized with the com-
bination of antibodies against the heavy neurofilament
subunit (NF-H) and the SC121 epitope as generic axonal
and transplant-derived cell markers, respectively. The nu-
clear mitotic marker Ki67, the early neuronal marker
TUJ1 and the astroglial cell marker GFAP were also used
in separate co-localization experiments with HNu or
SC121 as described elsewhere [22, 24, 26, 27]. All antibody
information is listed in Table 1. The Gallyas silver staining
method [28] was used to evaluate injured and/or degener-
ating axons and terminals. For this purpose, sections were
processed with a commercially available kit (NeuroSilver
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described previously [29].
Stained sections were studied on a Zeiss Axiophot
microscope equipped for epifluorescence (Diagnostic In-
struments Inc., Sterling Heights, MI, USA) or a Zeiss
LSM 510 inverted confocal microscope (Carl Zeiss Inc.,
Oberkochen, Germany). Confocal microscopic images were
captured with pinhole set at 0.8 μm to ensure co-localization
of multiple labels at the same resolution level as semithin
sections. Three-dimensional reconstruction by Z-stack
scanning through regions of interest was acquired with
LSM software (Carl Zeiss Inc., Oberkochen, Germany).
Adobe Photoshop 7.0 software (Adobe Systems, San
Jose, CA, USA) was used for montaging and image pro-
cessing. All staining, image collection, and quantification
were done in a fashion blind to group assignment.
Ultrastructural immunohistochemistry
Myelin formation by transplanted hOPCs was assessed
ultrastructurally with electron microscopy using stand-
ard pre-embedding immunoperoxidase-3,3'-diaminoben-
zidine IHC for the human cytoplasmic antigen SC121 as
described previously [23–25, 30]. Briefly, brain sections
prepared as in the previous section were treated with a
solution containing 4 % paraformaldehyde and 0.2 %
glutaraldehyde for 24 hours. Sections were then rinsed
in 0.1 M phosphate buffer (pH 7.3) for 3 to 10 minutes,
immersed in 1 % osmium tetroxide for 15 minutes,
dehydrated in graded concentrations of ethanol, embed-
ded in Poly/Bed 812 (Polysciences Inc., Warrington, PA,
USA), polymerized at 60 °C for 72 hours, and then fi-
nally embedded in BEEM® capsules (Electron Micros-
copy Sciences, Hatfield, PA, USA). Half the sections
were stained en block in uranyl acetate prior to embed-
ding. Serial ultrathin sections were collected on Formvar-
coated slotted grids and viewed with a Hitachi H7600
transmission electron microscope equipped with a 2 k×2
k bottom mount AMT XR-100 CCD camera (Hitachi
High-Technologies Corporation, Tokyo, Japan). Only sec-
tions that were not stained with uranyl acetate were used
for studying ensheathment profiles originating in hOPC
transplants.
Stereological quantification of human oligodendrocyte
progenitor cell survival and differentiation
Numbers of surviving hOPCs were counted in serial,
systematically and randomly sampled coronal sections
based on the optical fractionator concept with the aid of
a motorized stage Axioplan microscope (Carl Zeiss Inc.)
equipped with Stereo Investigator (MicroBrightField Bio-
science, lliston, VT, USA) as described previously [22].
To evaluate the migration and possible final residing lo-
cation of differentiating hOPCs, only the contralateral
side of transplantation was examined. hOPCs in corpuscallosum and cortex were also counted separately for this
purpose. Every twelfth serial coronal section through the
transplant/injury site was selected for stereological ana-
lysis. The counting frame was set at 50×50 μm and the
sampling grid and counting depth were 200×200 μm and
10 μm, respectively. Cells around the transplantation site
were not counted because of difficulties in discerning indi-
vidual cells in the densely packed center of the transplant.
Differentiation of survived hOPCs was estimated in a
non-stereological fashion as described previously [27].
Briefly, we counted the total number of SC121(+) cells,
as well as cells dually labeled with SC121 and the mature
oligodendrocyte marker MBP from our immunofluores-
cent preparations, on randomly selected fields of cortex
and corpus callosum using 40× magnification and avoid-
ing the transplantation site. At least three fields in each
of four serial sections were used from each animal.
Numbers of SC121(+) and double-labeled profiles were
pooled from each case and grouped per experimental
protocol. Average numbers of single- and double-labeled
cells were generated for two TBI groups and one Sham
group (n = 5 per group). Differentiation rate was
expressed as percentage of SC121 and MBP double-
labeled cells in the population of SC121(+) cells.
Migration mapping of oligodendrocyte lineage cells
derived from human oligodendrocyte progenitor cell grafts
The positions of all SC121(+) cells were mapped on every
twelfth coronal section through brain levels containing
the grafted cells and their lineage using Neurolucida soft-
ware (MicroBrightField Bioscience). Representative cells
differentiated from hOPCs and their processes were also
traced with Neurolucida software.
Statistical methods
Variance between and across samples of numbers of
oligodendrocyte-lineage cells classified by experimental
history (IA versus sham), migratory destination in brain
(corpus callosum versus neocortex), and time point after
transplantation (6 weeks or 3 months) was analyzed with
two-way analysis of variance (ANOVA) or t test. In the
case of ANOVA, significant differences were further ana-
lyzed with post hoc tests to reveal important main effects
or interactions. Statistical analyses were performed with
STATISTICA 8.0 (StatSoft Inc., Tulsa, OK, USA).
Results
Axonal injury in nude rats using the impact acceleration
model
Immunocompromised nude rats were used here to avoid
immune rejection of human cell xenografts into rodent
brain [20]. Because the original IA model was developed
in Sprague-Dawley [16] and Wistar [31] rats, we first ex-
plored whether the same IA settings as the ones used in
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TAI was studied with IHC strategies routinely used in
TBI studies - that is, antibodies against APP, the mono-
clonal antibody RMO14 binding to the rod domain of
neurofilament heavy and medium chains that are ex-
posed after lesion-induced sidearm proteolysis, and a
monoclonal antibody against the 68-kDa light chain neu-
rofilament protein (NF68). IHC was used in brain sec-
tions from nude rats exposed to a standard severe IA
injury (450 g weight drop from a height of 2 meters)
[16]. Tissues were also processed with a modification of
the Gallyas silver method. Twenty-four hours post-
injury, APP, RMO14 and NF68 IHC consistently labeled
axonal pathologies such as undulated axons, axonal
swellings and bulbs in the corpus callosum and the cor-
ticospinal tract as described in several published studies
[32–35] (data not shown). Argyrophilic axonal degener-
ation based on Gallyas silver staining became evident 1
week post-injury in the corpus callosum (Fig. 1a), the
optic tract and the corticospinal tract (Fig. 1b). Axonal
degeneration labeled with Gallyas silver was still present
in the corpus callosum (Fig. 1c), corticospinal tract
(Fig. 1d) and other white matter tracts 3 months post-
injury. These data suggest that the pattern of TAI in
nude rates exposed to IA injury is qualitatively similar to
the one described for Sprague-Dawley and Wistar ratsFig. 1 Traumatic axonal injury in impact acceleration-injured nude rats as d
nude rats to severe impact acceleration injury, argyrophilic axonal degeneratio
tract (arrows). c,d At 3 months after injury, degenerating axons are still ev
(arrowhead). Scale bars = 50 μmand, therefore, the nude rat model is suitable for re-
search into hOPC transplantation outcomes in a diffuse
TBI background.
Differentiation of human embryonic stem cells to human
oligodendrocyte progenitor cells in vitro
As per Hu and colleague’s original description [18, 19],
columnar epithelial cells began to appear and organize
into rosettes 10 days after induction of differentiation of
embryoid bodies with human ESC medium without
fibroblast growth factor (FGF)2 (DMEM/F12, Knockout
serum replacer, MEM-nonessential amino acid, 0.1 mM
β-mercaptoethanol, 4 ng/mL FGF2) for 3 days and then
with neural differentiation medium (NDM; DMEM/F12,
N2, MEM-nonessential amino acid, 2 ug/mL heparin)
for 6 days. Neuroepithelial cells were initially cultured in
the presence of 0.1 μM retinoic acid on laminin-coated
plates for 4 days as described by Hu and colleagues [18].
The resulting rosette-rich colonies were manually detached
and grown into spheres and then continued to be pat-
terned with retinoic acid and SHH for 10 more days. To
generate pre-oligodendrocyte progenitors, spheres were
passaged by Accutase and cultured in NDM supplemented
with B27, SHH (100 ng/mL) and FGF2 (10 ng/mL) for 10
days. For further differentiation into hOPCs, spheres were
cultured in GDM (DMEM/F12, N1, B27, MEM-emonstrated by Gallyas silver staining. One week after exposure of
n is pronounced in (a) the corpus callosum and (b) the corticospinal
ident in these regions (arrows). Axonal bulbs are also present in (d)
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μg/mL biotin) supplemented with SHH, PDGF-AA, IGF1
and NT3 for 2 weeks and then dissociated by Accutase
and continued to be feed with the same GDM without
SHH (day 49). Every 2 or 3 weeks, the spheres were
passaged by the same dissociation method using Accu-
tase and cultured in the same GDM with PDGF-AA,
IGF1 and NT3. On day 84 after induction of differenti-
ation, spheres were trypsinized into dissociated hOPCs,
plated and cultured further as in Materials and methods.
On day 98, cells were detached from the plate and resus-
pended at a high concentration (2.0 × 108 per mL) for
transplantation.Fig. 2 Characterization of human oligodendrocyte progenitor cells used fo
embryonic stem cells. (a) No mesodermal lineage cells were detected (bone m
epitope J1; TUJ1) and (c) astrocyte (glial fibrillary acidic protein; GFAP) markers
cells (90-95 %) were positive for early and late OPC and pre-oligodendrocyte
and (f) O4). Fifty percent of cells were (g) NG2 positive and (h) most cells wer
showed varied expression of the oligodendrocyte marker myelin basic protein
profiles in these human OPC cultures. Inset in (b) is taken from a culture that
are magnifications of cells or groups of cells labeled with asterisks to showcas
non-nuclear (d,e,f,g,i) localizations. Other than the nuclear localization of the t
prominent in processes (e,g) or have punctate peripheral localization (f,i). ScalAs described in Materials and methods, the cell com-
position of hOPC transplants was analyzed in a repre-
sentative sample of cells destined for transplantation
with immunocytochemistry for protein markers of vari-
ous neural cell lineages [36–39] (Fig. 2). Results show
that only a small percentage of hOPCs (less than 10 %)
expressed the neuronal marker TUJ1, an even smaller
percentage (less than 1 %) were positive for astrocytic
markers (GFAP), and no bone morphogenetic protein(+)
mesodermal-lineage cells were detected (Fig. 2a-c). In
contrast, these hOPC samples were enriched for cells
expressing oligodendrocyte-lineage markers including
A2B5, PDGFRα, O4, NG2, Sox10 and MBP (Fig. 2d-i).r transplantation 99 days after induction of differentiation of human
orphogenetic protein; BMP) and very little (b) neural (type III-tubulin
were expressed in the oligodendrocyte progenitor cells (OPCs). Most
markers ((d) A2B5, (e) platelet-derived growth factor receptor (PDGFR)α
e positive for the transcriptional factor Sox10. (i) About 50 % of cells
(MBP). Insets in (b) and (c) show typical rare neuronal and astrocytic
was double immunostained for NG2 (green) and TUJ1 (red). Insets in (d-i)
e typical cytologies and immunoreactivities, including nuclear (h) and
ranscription factor Sox10 (H), most immunoreactivities are especially
e bars = 20 μm
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oligodendrocyte progenitor cells in the rat brain
Human OPCs were transplanted into the deep sensori-
motor cortex of IA- and sham-injured rats. Transplanted
hOPCs survived very well in the brains of injured and un-
injured animals and migrated extensively away from the
transplantation site in both groups. We mapped and
counted migratory profiles at 6 weeks and 3 months post-
transplantation. For the time point of 6 weeks we have
data only on IA-injured animals. In the case of 3 months,
we have data from both IA-injured and sham animals.
At 6 weeks, there was some migration of transplant-
derived SC121(+) human cells into the ipsilateral corpus
callosum and external capsule and into the contralateral
corpus callosum adjacent to cingulate gyrus (Additional
file 2: Fig. S2). At 3 months, transplanted cells had mi-
grated much further (Figs. 3 and 4). hOPCs had densely
populated the ipsilateral corpus callosum and the entire
length of the external capsule and reached further into
the corpus callosum and external capsule on the contra-
lateral side; some cells had entered the contralateral neo-
cortex (Fig. 4). In many cases, these cells had migrated 5
mm or more in antero-posterior distance from the
transplantation site (Fig. 4). There was little migration
into the gray matter, and cortical invasion of hOPCs was
limited to layers adjacent to corpus callosum (lower
layer 6). In the case of migration into the neostriatum
(Fig. 4), hOPCs were localized strictly inside the white
matter striae.
Stereological counts of transplant-derived cells contra-
lateral to the injection side provide a good measure ofFig. 3 Extensive migration of transplant-derived cells 3 months post-transp
injured rat shows that SC121(+) cells (brown) migrate extensively from the
sides. Methylene green was used as counterstain. Arrows denote human o
the frames to convey information on cytologythe migratory potential of transplanted hOPCs. Cell
counts in IA-injured animals at 6 weeks and 3 months
show massive and progressive migration into the corpus
callosum and adjacent cortical layer 6 (Fig. 5). For ex-
ample, the number of oligodendrocyte-lineage cells in
the contralateral corpus callosum is 30 times higher at 3
months compared to 6 weeks (Fig. 5a). Two-way
ANOVA examining interaction between time and loca-
tion shows that time tends to advance the position of
cells from the corpus callosum into deep cortical layers
(Fig. 5a). Experimental history (IA versus sham) shows
no effect on numbers of oligodendrocyte-lineage cells in
corpus callosum or cortex at 3 months. There are about
three to four times as many oligodendrocyte-lineage
cells in corpus callosum compared to cortical layer 6 in
both IA-injured and sham animals (Fig. 5b). Two-way
ANOVA addressing the interaction between experimen-
tal history and location shows no significant effect (that
is, lesion does not promote more advanced migration
into deep cortical layers).
At 3 months post-transplantation, a majority of
oligodendrocyte-lineage cells around the transplant-
ation site (the triangular region of Fig. 3) had round
perikaryal profiles and multiple radial processes con-
sistent with type I morphology (Fig. 6a-c) [40]. On
the other hand, the majority of transplant-derived
cells in the corpus callosum were spindle-shaped with
parallel processes consistent with type II morphology
(Fig. 6d-f ) [40]. In the gray matter away from the in-
jection site (ipsilateral or contralateral), cytology was
mixed.lantation. This representative section from an impact acceleration-
transplantation site (arrowhead) along the corpus callosum on both
ligodendrocyte progenitor cell distribution. Insets are enlarged from
Fig. 4 Migration map of human oligodendrocyte progenitor cell transplant-derived cells from a representative case of an impact acceleration-
injured rat. Images were acquired and processed from serial coronal sections (40 μm; every 24th) from a case of an impact acceleration-injured
rat 3 months post-transplantation using Neurolucida software. Distance between neighboring sections is 0.96 mm. Distance between migrating
cells in section 9 and edge of transplantation site (section 4) is 4.8 mm. The maximal migration at 3 months was greater than 5 mm based on
the fact that section 9 was not the furthest section containing human cells (other sections are not shown)
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site or within the main migratory domains (corpus callo-
sum and deep neocortex) were positive for the mitotic
marker-Ki67 at 6 weeks or 3 months, in injured or sham
animals. This pattern suggests that, at the time points
studied here, surviving cells are not proliferative at the
original transplant site or in their migratory paths and
destinations (Fig. 7).
Differentiation of transplanted human oligodendrocyte
progenitor cells in the rat brain
At 6 weeks and 3 months post-transplantation, under
either IA or sham conditions, no neurons and very few
astrocytes were derived from transplanted hOPCs
(Fig. 8a,b). The majority of transplanted cells were identi-
fied as PDGFRα(+) (Fig. 8i-k) or MBP(+) (Fig. 8c-h) profiles
in both the transplantation site and migratory pathways/
destinations. MBP immunoreactivity was expressed in both
round and spindle-shaped oligodendrocyte profiles derived
from the transplant (Fig. 8c-h). At 3 months, most
transplant-derived cells around the transplantation site, in
corpus callosum, and deep cortical layers were also APC(+)
(Fig. 8l-n).
In the area surrounding the transplantation site of IA-
injured animals, cell counts of PDGFRα(+) profiles show
that 74.6 ± 9 % of graft-derived cells are PDGFRα(+) at
6 weeks post-transplantation; this number is significantly
reduced to 49.4 ± 11 % at 3 months. Conversely, the per-
centage of MBP(+) oligodendrocytes derived from hOPCs
is significantly higher at 3 months (67.8 ± 12 %) compared
to 6 weeks (37.1 ± 9 %) (Fig. 9a, left). A similar pattern isseen in the corpus callosum (Fig. 9a, right), but trends in
this case do not reach statistical significance. In the area
surrounding the transplantation site, there are no signifi-
cant differences in PDGFRα(+) or MBP(+) cell rates be-
tween sham and injured animals (Fig. 9b, left). In the
corpus callosum, the percentage of MBP(+) cells is signifi-
cantly higher in injured animals compared to shams
(Fig. 9b, right).
Confocal microscopy with three-dimensional image re-
construction for SC121- and NF-H-immunoreactive
structures was used to visualize appositions between
SC121(+) processes belonging to transplant-derived cells
and NF-H(+) SC121(−) host axons. Reconstructed con-
focal images demonstrated many ensheathing appositions
between processes of transplant-derived oligodendrocytes
and host axons (Fig. 10).
Ultrastructural IHC for the human cytosolic epitope
SC121 was used to disclose the involvement of
transplant-derived oligodendrocyte processes in the en-
sheathment of host-derived axons or the formation of
myelin. In a pattern similar to the one revealed with
confocal microscopy, semi-thin preparations accom-
panying thin sections showed SC121(+) processes co-
localizing with toluidine blue-stained myelin sheaths
(Fig. 11a). Using thin sections, we found numerous
SC121(+) cytoplasmic projections juxtaposed to or en-
sheathing unlabeled (host) axons. Ensheathment was fea-
tured by complex configurations, including the presence
of outer and inner cytoplasmic tongues and close juxta-
positions with compact myelin (Fig. 11b,c). It was not
possible to ascertain whether compact myelin belonging
Fig. 5 Stereological counts of transplanted human oligodendrocyte
progenitor cells migrating into the contralateral hemisphere. a
Migratory patterns at two time points (6 weeks and 3 months) after
transplantation in two brain regions (corpus callosum and deep
cortex) in impact acceleration (IA) animals. b Migratory tendencies in
the same two locations based on experimental history (IA versus
sham) at 3 months post-transplantation. In (A), the difference in cell
numbers between 6 weeks and 3 months is significant by t test
(*P < 0.05) in both corpus callosum and deep cortex (layer 6); two-
way analysis of variance (ANOVA) shows that there is interaction
between time and location (that is, time tends to favor deep cortical
over callosal location; P < 0.05). In (B), there are no differences in cell
numbers between sham and IA-injured subjects in corpus callosum
or deep cortex at 3 months post-transplantation. In both groups of
subjects, there are more cells in corpus callosum than deep cortex
by t test (P < 0.05). Two-way ANOVA shows that there is no interaction
between experimental history and location (that is, injury does not
seem to influence the location of cells in one site over the other). OPC,
oligodendrocyte progenitor cell
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tinuous with the latter in our preparations because the
cytoplasmic human epitope SC121 would not be ex-
pected to be present within dense myelin.Discussion
Our findings indicate that the IA model of Marmarou
can be effectively replicated in the nude rat background.
Using the nude rat IA model, hOPC transplants survive
well in the deep sensorimotor cortex and behave in a
fashion very different from NPs; that is, they migrate
massively and show almost exclusive affinity for white
matter tracts, especially the corpus callosum and adja-
cent white matter in deep cortical layers. The progres-
sive migration of transplanted hOPCs is accompanied by
progressive maturation into MBP(+) and APC(+) oligo-
dendrocytes that ensheath host axons. Our findings pro-
vide further support to the notion that human ESCs and
neural stem cells can be coaxed to specific fates that
continue to progress to fully differentiated progenies
after transplantation into the adult CNS. These progen-
ies behave in a fashion that is strikingly similar to indi-
genous differentiated neural cells. Given the very low
level of proliferation of transplanted cells as early as 6
weeks post-transplantation and their prompt differenti-
ation into mature oligodendrocytes, the possibility of
overgrowth and, hence, tumorigenic risk is very low. We
postulate that the high numbers of cells present in the
contralateral hemisphere by 3 months had started as
pre-existing hOPCs in the dense center of the transplant
and did not derive from ongoing cell divisions.
The use of human ESCs such as line H9 was based
on a number of considerations including: thorough
characterization and inexhaustible supply of the parent
line [41–44]; great versatility to differentiate to any
neural cell type in sufficient quantity for transplant-
ation [18, 43–50]; and well-established methods for
in vitro manipulation to fate determination prior to
transplantation. The choice of human ESCs is based on
availability and access considerations, the greater trans-
lational value of such cells, and a long experience in
our laboratory using human cells as transplants in ro-
dent hosts [21–24, 27, 50–54].
In adulthood, the sources of usable stem cells or
neural progenitors in the CNS are limited to a few fore-
brain niches, and the yield or repair potential of such
niches is low. For example, in mouse models of multiple
sclerosis, the limited recruitment of endogenous hOPCs
into demyelination sites does not suffice for effective
remyelination [55]. Therefore, supplementation of such
limited stem cell pools with exogenous progenitors is a
reasonable first step for a cellular therapy. Besides pro-
viding sources of fully differentiated nerve cells compe-
tent to replenish lost cells, transplanted progenitors
also release neuroprotective molecules [27, 56] and, im-
portantly, may induce endogenous stem cells/progeni-
tor cells to proliferate and differentiate as auxiliary
niches, thereby improving the efficacy of self-repair
mechanisms [52].
Fig. 6 Some cytological features of human oligodendrocyte progenitor transplant-derived cells 3 months post-transplantation. a-c Around the
transplantation site, a large number of transplant-derived SC121(+) cells (brown) have round features with extensive and radially arrayed processes.
d-f In the corpus callosum (cc), the majority of SC121(+) cells are spindle shaped with long parallel processes. (b,e) Enlargements of bracketed areas in
(a) and (d), respectively. (c,f) Neurolucida tracings of representative cells from (b) and (e) indicated with asterisks. Scale bars: (a,d) = 50 μm; (b,e) = 20 μm
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from human embryonic stem cells
In the body of in vivo studies reported here, we used
hOPCs that were prepared from human ESC line H9 fol-
lowing the methods described by Hu and colleagues with
minor modifications [19, 45, 57]. Our experience with cul-
turing and differentiating H9 cells and then characterizing
the derived hOPCs in vitro is very similar to the original
description of Hu and colleagues; hOPCs derived in this
manner express PDGFRα, NG2, O4, and Sox10, a patternFig. 7 Proliferative activity of human oligodendrocyte progenitor cells at 6 wee
cells (red) are Ki67(+) cycling cells (green) (arrow, the color turns into yellow bec
site at 6 weeks (a) or, after migration, in the corpus callosum (cc) at 3 m
rat. Scale bars = 50 μmconsistent with a classical hOPC identity [36]. Methodo-
logical issues concerning hOPC derivation are very import-
ant, because the use of highly concentrated hOPCs for
grafting is key for achieving the desired outcomes (that is,
myelination of host axons) within a limited time period.
Differentiation of human ESCs into hOPCs is a longer
and more arduous process than the one leading to neur-
onal progenitors. In work reported here we initially used
two methods [18, 58] for deriving and characterizing
hOPCs prior to transplantation. In our hands, theks and 3 months post-transplantation. Only rare HNu(+) transplant-derived
ause of overlapping with red color from HNu) at the transplantation
onths (b). Images are from a representative impact acceleration-injured
Fig. 8 (See legend on next page.)
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Fig. 8 Differentiation of transplanted human oligodendrocyte progenitor cells at 3 months post-transplantation. All images are from representative
impact acceleration-injured animals. a At 3 months, we found no SC121(+) cells expressing type III-tubulin epitope J1 (TUJ1(+)) neuronal phenotypes,
and only rare SC121(+) human oligodendrocyte progenitor cells (hOPCs; red) had differentiated into glial fibrillary acidic protein (GFAP(+)) astrocytes
(green) at the transplantation site (arrow). Inset in (a) is a magnification of the astrocytic profile indicated by the arrow in the main panel. b In the
corpus callosum (cc), no hOPCs (red) are immunoreactive for GFAP (green). c-h Confocal images to show that various types of cells derived from the
hOPC transplant (round in (c) or spindle-shaped in (f), red) become mature myelin basic protein (MBP) (+) oligodendrocytes (green in (d) and (g)); both
cell bodies (arrows) and processes (arrowheads) of transplant-derived cells are immunoreactive for MBP. i-n Platelet-derived growth factor receptor
(PDGFR)α(+) (i-k) and adenomatous polyposis coli protein (APC) (+) (l-n) cell bodies of transplant-derived cells in the corpus callosum. (e,h,k,n) Merged
images of panels (c,d), (f,g), (i,j) and (l,m), respectively. Scale bars: (a,b) = 50 μm; (c-n) = 20 μm
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cessful in generating viable transplants, although this
observation was not confirmed in a systematic fashion.
Major differences between the two methods are:
trophic factors used; extracellular matrix used; enzyme
used to passage the cells; length of time in three-
dimensional culture; and timing of hOPC harvest. In
previous published work, the method of Nistor and
colleagues generated hOPCs with good viability afterFig. 9 Population sizes of platelet-derived growth factor receptor α- and m
oligodendrocyte progenitor cell transplant. a Differentiation patterns at 6 w
callosum versus transplantation area in cortex) in impact acceleration (IA) a
experimental history (IA versus sham) at 3 months post-transplantation. In
fewer platelet-derived growth factor receptor (PDGFR)α(+) transplant-derive
performed at the transplantation site. In (b), IA rats at 3 months have more
corpus callosum (cc). *P < 0.05transplantation [58–62], but the transplantation site of
these authors (spinal cord) was different from ours
(neocortex). Interestingly, the same team of investiga-
tors reported that their hOPCs did not survive past 2
weeks after transplantation in animal models of mul-
tiple sclerosis, but these mice were immunocompetent
C57B6 mice [63]. Our in vivo outcomes using hOPCs
prepared as per Hu and colleagues are consistent with
the ones reported by that team on shiverer mice [19].yelin basic protein-immunoreactive cells derived from human
eeks and 3 months after transplantation in two brain regions (corpus
nimals. b Differentiation patterns in the same two locations based on
(a), IA rats at 3 months have more myelin basic protein (MBP) (+) and
d oligodendrocytes than at 6 weeks post-transplantation; counts were
transplant-derived MBP(+) oligodendrocytes compared to sham in the
Fig. 10 Ensheathment of axons by transplant-derived
oligodendrocytes. This three-dimensional reconstructed confocal
micrograph depicts SC121(+) process (red) from transplant-derived
oligodendrocytes ensheathing neurofilament H(+) axons (NFH, green)
in a representative impact acceleration-injured animal at 3 months
post-transplantation (arrows on z plane). Ensheathment is confirmed
on x and y planes at the corresponding cross-sectional locations (arrow
heads). Scale bar = 10 μm
Fig. 11 Ensheathing profiles issued by transplant-derived
oligodendrocytes as shown by ultrastructural immunohistochemistry.
Preparations are from an injured animal 3 month post-transplantation.
a Companion toluidine blue-stained semi-thin section through the
corpus callosum shows the co-localization of SC121(+) (brown)
processes with blue myelin sheaths in transverse (arrow) axonal
profiles. Co-localization profiles are dark brown. Asterisk shows a
group of SC121(−) axons. b An SC121(+) process (arrowhead) is
shown to ensheath an unlabeled axon. This profile is adjacent to
one SC121(+) cell (1) and also one unlabeled cell (2). Cells 1 and 2
have the appearance of oligodendrocytes. c A magnification of the
framed area in (b) shows detailed ultrastructural features of
ensheathment by transplant-derived oligodendrocytes. SC121(+)
tongue processes (arrowheads) are wrapped around a myelinated
axon. Myelin sheath on the inside appears to be unlabeled. Scale
bars: (a) = 5 μm; (b) = 1 μm; (c) = 500 nm
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oligodendrocyte progenitor cell transplants
Two important trends in hOPC maturation were the
progressive phenotypic differentiation in the transplant-
ation area and the higher rate of maturation of hOPCs
in the corpus callosum of injured subjects. With respect
to the former, we have observations only from IA-
injured animals, but we speculate that there is a similar
differentiation trend in control (sham) animals. We also
postulate that differentiation trends in the corpus callo-
sum are not too dissimilar to those in the cortex around
the transplantation site and that differences in signifi-
cance may be caused by the fact that hOPC maturation
may be earlier in the white matter [64] compared to grey
matter. Regarding the latter, it would appear that injury
may contribute to hOPC differentiation; the difference
between corpus callosum and cortex around the trans-
plantation site may be due to the fact that cortex is not
a primary site of injury in the IA model that preferen-
tially affects white matter tracts. We have previously re-
ported that the injured spinal cord niche influences both
the proliferation and differentiation of human CNS stem
cells propagated as neurospheres [65].
The role of injured or otherwise pathological environment
as a niche for differentiation deserves further commentary.
Environments associated with acquired neurological injury
such as stroke and spinal cord injury have been shown to
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and this effect may be mediated, in part, by trophic and
cytokine signals such as stem cell factor [68], stromal
cell-derived factor 1α [69], FGF-2 [70], vascular endo-
thelial growth factor [71], ciliary neurotrophic factor,
and CXC chemokine receptor 4 [72]. Some of these fac-
tors are known to act as tropic cues for migration or to
specify the definitive phenotype of endogenous or ex-
ogenous stem cells [68, 73–79].
The invasion of migrated hOPCs and their differenti-
ated progenies into deep cortical layers matches native
cortical myelination patterns; these patterns show an
overall denser myelination in lower cortical layers and
variable myelination in superficial layers. It is also inter-
esting that, at least up to 3 months post-transplantation,
the differentiated progeny of transplanted hOPCs does
not advance to more superficial layers. This distribution
is identical to that of native mature oligodendrocytes; in
contrast to hOPCs that are radially spread across cortical
layers, oligodendrocytes favor deep layers and follow the
deep-to-superficial-layer myelin gradient [80].
The presumed intent of OPC transplants as cell ther-
apies is the replenishment of damaged or destroyed
myelin sheaths. Although molecular myelin markers
such as MBP may be telling of the myelin-forming po-
tential of OPCs and their progenies, they do not directly
show that MBP(+) cells are forming myelin. The three-
dimensional reconstruction of confocal images indicates
a close, ensheathment-like, apposition of host axons with
processes of transplant-derived oligodendrocytes, but the
presence of structurally mature myelin can only be
ascertained ultrastructurally. Using ultrastructural IHC
or electron microscopy combined with histochemistry,
previous studies have demonstrated the ability of specific
progenies of neural stem cells or OPCs to ensheath [21]
or increase the thickness of abnormal myelin sheaths in
hosts [19, 26, 59, 61, 81, 82], but labeling of exogenously
derived myelin is technically difficult. In the present
study, ultrastructural IHC divulges that transplant-
derived cells ensheath host axons in intimate proximity
to myelin sheaths, but the host-versus-transplant identity
of the myelin itself is difficult to ascertain. The human
cell marker SC121 is a cytosolic marker and, therefore, it
is found in oligodendrocyte cytoplasmic projections and
ensheathing tongues but not in the membranous myelin
sheath itself. Unstained preparations that were used here
have not been particularly useful, primarily because of
this reason. Furthermore, existing myelin antibodies can-
not resolve between human and rodent myelin and this
problem limits their usefulness in confocal microscopy
or ultrastructural IHC.
Ultimately, the proof of concept that remyelination or
myelin remodeling by OPC transplants can be beneficial
in TAI/DAI will depend on the demonstration that suchexogenous OPCs afford functional benefits. In the case
of IA-injured rodents, such benefits can be sought out in
a number of behavioral domains. One approach is as-
sessment of motor control, which depends on the intact-
ness of the corticospinal tract. Experiments addressing
functional repair with exogenous OPCs have been
successfully performed in models of spinal cord injury
[10, 11] and demyelination [82–85]. In TBI models, motor
recovery may occur within the first month after injury in
the absence of any therapy, making the assessment of
the efficacy of cell therapies more challenging. In such
models, the assessment of efficacy or human neural cell
therapies may be more straightforward using tasks of
cognition or anxious/emotional disposition, faculties
that become chronically impaired in rodent TBI. Chronicity
of deficits is important because these human cells may
take months to proliferate, migrate and terminally differ-
entiate [15].
Stem cell transplantation as experimental therapy for
traumatic brain injury
Some success in models of ischemic brain injury [9] has
encouraged the use of stem cell/NP transplantation in
models of focal TBI [10, 86]. However, because of the
complexity of TBI and its animal models, there is a need
to identify specific repair targets based on key patho-
logical mechanisms. Such repair tasks include replacing
dead neurons, supporting injured neurons, and protect-
ing axons or assisting with axonal repair/regeneration.
The problem of neuronal injury/death is encountered
both in focal injury [87, 88] and in the course of TAI
[89, 90]. Neuronal cell death in focal TBI is acute and
has necrotic components, whereas in TAI/DAI it is slow
with apoptotic features and may be associated with
retrograde and trans-synaptic effects [8, 89, 91]. Al-
though axonal repair/remyelination as a therapeutic target
separate from neuronal regeneration is best established in
spinal cord injury [11], there is evidence that demyelin-
ation may contribute to degeneration of axons in TAI
[12, 13]. Therefore, contributing exogenous hOPCs in the
case of TAI may assist in remyelination and prevent axonal
degeneration and disconnection within brain circuits.
There is very little published work on stem cell-based
therapies for models of TAI/DAI. However, the field of
TBI and more specifically TAI/DAI can borrow from
spinal cord injury that invariably involves trauma in long
tracts [59, 60, 92–96]. Experimental cell therapies in ani-
mal models of spinal cord injury have utilized various
stem cell preparations including neurospheres and OPCs
[59, 60, 96, 97], and there are several ongoing clinical tri-
als using neural stem cells [98, 99]. In one report, OPCs
were found to remyelinate and restore locomotion after
contusional spinal cord injury in rodents [59], but func-
tional recovery reported in this study occurred within 12
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spect to migration and terminal differentiation of OPCs.
In contrast to spinal cord injury, where long tracts
course in relatively circumscribed areas, DAI involves
disparate white matter tracts [100, 101] and it would be
difficult to transplant cells into all these sites. Therefore,
transplantation route (systemic, ventricular, and parenchy-
mal) and location of transplant (in the case of parenchy-
mal delivery) are critical. The choice of transplantation
site may be based on factors such as concentration of
axonal pathology or sites of injury responsible for critical
symptoms. The choice of transplantation into deep sen-
sorimotor cortex in the present study was based on the
expectation that this site would provide oligodendrocytes
for both the corpus callosum and the corticospinal tract,
which are affected in the IA injury [16, 35]. Our findings
indicate that there was little, if any, invasion of cells into
the internal capsule by 3 months, but the extensive migra-
tion of OPCs via the corpus callosum and descending
tracts and their remarkable differentiation into mature oli-
godendrocytes predicts a broader remyelination potential
with longer survival times. Of course, transplantation sites
can also be optimized to the desired functional outcome
or involve multiple locations as we have shown in models
of motor neuron disease [23, 52, 53].
Conclusions
In conclusion, the findings in this study support the idea
that hOPCs can serve as a competent source of mature
oligodendrocytes that ensheath CNS axons after TAI,
and provide proof of concept that regenerative strategies
targeting myelin remodeling can be further considered
in TBI models in the future. In addition, we demonstrate
that the nude rat is a suitable animal model for studying
human cell transplants in neurotrauma. In view of the
fact that stem cell therapies are being progressively in-
troduced in clinical trials of neurodegenerative and trau-
matic diseases of the CNS [11, 98, 102–108], these
timely results should encourage further translational
work targeting the problem of axonal degeneration in
the context of DAI and, specifically, interventions de-
signed to regenerate or remodel the myelin sheath.
Additional files
Additional file 1: Fig. S1. A schematic illustration (A) of the method
used to prepare hOPCs for transplantation and representative cultures and
cells derived (B). Method sketched in A was based on Hu and colleagues
[18] with minor modifications in the final stage before transplantation (day
84–99). Panel B shows representative morphologies of hOPCs on days 3, 7,
12, 17, 23, 27, 41, 90 and 97 that roughly correspond to milestones in A.
Human ESC H9 colonies were detached by dispase on day 1 to prepare
embryoid bodies (EBs) that were subsequently cultured for 3 days in hES
medium without FGF (B, Day 3) and then for 3 days in NDM. Embryoid
bodies (B, Day 7) were then plated on laminin-coated plates and cultured
with NDM for 3 days and NDM with RA for another 5 days (B, Day 12). Onday 15, colonies were manually detached and cultured as spheres (B, Day
17) for 10 days in NDM with RA, B27 and SHH. On day 24, big spheres (B,
Day 23) were dissociated by Accutase (ACT) into small spheres (B, Day 27)
and cultured with NDM containing B27, SHH and FGF for 10 days. On day
35, medium was switched to GDM with SHH, PDGF, IGF and NT3 and
cultured for 2 weeks (B, Day 41). On days 49 and 70, cells were passaged
with Accutase treatment and treated with GDM with PDGF-AA, IGF1 and
NT3 for the remaining of the protocol. On day 84, spheres were trypsinized
and plated on p-L-ornithine and laminin-coated plates and coverslips
and cultured for 2 weeks in the same medium for transplantation or
immunocytochemistry, respectively. On day 99, cells were trypsinized
with TrypLE, counted, resuspended in high concentration and used for
transplantation (* in A). Scale bars in B: Day 12, 500 μm, Day 3 and 17;
200 μm, all others; 100 μm.
Additional file 2: Fig. S2. Migration of transplant-derived cells at 6
weeks and 3 months post-transplantation. Photographs are taken
through the corpus callosum on the side contralateral to transplantation
from representative animals. Panel A shows a few scattered SC121(+)
profiles at 6 weeks. At 3 months post-transplantation (B), there are
numerous SC121(+) cells that had migrated from the transplantation site.
Insets are enlargements of framed areas in main panels. Scale bars: 100 μm.
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